Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a large drop in short interest in January. As of January 15th, there was short interest totalling 2,900 shares, a drop of 65.9% from the December 31st total of 8,500 shares. Based on an average daily volume of 300,500 shares, the short-interest ratio is currently 0.0 days.

Provectus Biopharmaceuticals Trading Up 2.2 %

OTCMKTS:PVCT traded up $0.00 during trading hours on Tuesday, reaching $0.12. The company’s stock had a trading volume of 40,450 shares, compared to its average volume of 212,674. Provectus Biopharmaceuticals has a one year low of $0.04 and a one year high of $0.22. The business’s 50-day moving average is $0.12 and its 200-day moving average is $0.11.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.